Dyne Therapeutics (NASDAQ:DYN) Shares Up 10.4% – What’s Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN) rose 10.4% on Thursday . The stock traded as high as $26.09 and last traded at $26.01. Approximately 235,707 shares traded hands during trading, a decline of 83% from the average daily volume of 1,423,980 shares. The stock had previously closed at $23.56.

Wall Street Analyst Weigh In

DYN has been the subject of a number of recent research reports. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 target price for the company. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $50.42.

Dyne Therapeutics Stock Up 7.6 %

The company’s 50 day simple moving average is $28.02 and its 200-day simple moving average is $34.54. The firm has a market cap of $2.58 billion, a P/E ratio of -7.12 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities research analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Insider Activity

In other news, Director Jason P. Rhodes sold 782 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now owns 15,962 shares in the company, valued at $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This trade represents a 19.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,742 shares of company stock worth $1,443,246. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DYN. Quantbot Technologies LP purchased a new position in Dyne Therapeutics during the third quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $36,000. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics in the third quarter worth approximately $62,000. Finally, KBC Group NV increased its position in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.